One missed rule can cost you your license.

There is a free tier, two subscription levels, and one-time reports. Free: subscribe with your email for the weekly MedSpaRadar Brief and see what changed across everything we watch — all 50 state legislatures, the FDA, and the Federal Register. Solo-State ($29/month — a launch rate through September 30, 2026, then $39) watches a single state daily with the full what-to-do on every change in it, plus federal and nationally-significant alerts. All-Access ($99/month founding for the first 50 practices, then $149) covers every state we monitor and adds your personalized, printable Compliance Brief, the GLP-1 Compounding Intelligence view, and the compliance checklists. Prefer to buy once? The $49 State Compliance Snapshot needs no subscription and is credited toward one if you subscribe within 30 days. Monitoring, not legal advice.

You can buy once — no subscription required. The $49 State Compliance Snapshot is an instant, source-linked report of every published med-spa and injectable change for your state, with the federal record included; if you subscribe within 30 days, the $49 is credited toward it. There is no longer a paid Peptide & GLP-1 pack: the federal standing of every substance we track, with the citation behind each one and its change history, is free on /tracker, and we withdrew the paid pack rather than charge for a page you can already read. All-Access members get the Snapshot included for their states. Monitoring, not legal advice.

They do different jobs, and most practices want more than one of them. MedSpaRadar is continuous monitoring: it reads all 50 state legislatures plus the FDA and Federal Register every day, and polls 40 further primary sources every 2 hours — the regulatory text itself, federal court dockets, drug labels and state licensing boards — scores each change for its impact on aesthetic practices, has a human review it, and tells you in plain language what changed and what to do, linked to the primary source. A trade association is membership, education, events and a peer community. A consultant or attorney applies the rules to your specific facts, which is something we will never do — we are not a law firm and this is not legal advice. Google Alerts match keywords; they do not parse bills or FDA actions for med-spa relevance. MedSpaRadar is the layer that tells you a rule moved, so you can take it to the people above. See our side-by-side comparison with AmSpa membership for published prices and what each includes.

It depends on two things that change frequently: whether the drug is on the FDA shortage list, and your state’s rules. Under federal law (sections 503A and 503B), a compounder generally may not make a copy of a commercially available drug — being on the FDA shortage list has been the main exception that allowed compounded semaglutide and tirzepatide. When the FDA declared those shortages resolved, the basis for compounded versions narrowed sharply. MedSpaRadar tracks FDA shortage status and state action daily so you know when it changes. This is regulatory monitoring, not legal advice.

It depends on whether the peptide is on the FDA’s 503A Bulks List — and as of the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meetings, none of the headline peptides are. PCAC recommended further review of BPC-157, KPV, TB-500, and MOTS-c, but a recommendation is not a legal status change: FDA is not bound by it, and actually permitting 503A compounding requires notice-and-comment rulemaking, commonly 8–12 months. So these remain not compoundable under 503A today. FDA has separately scheduled a further PCAC meeting by the end of February 2027 for five more peptides (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF). We track each substance’s current standing, with its government source and date, on the MedSpaRadar substance tracker. This is regulatory monitoring, not legal advice.

The MedSpaRadar substance tracker lists every peptide and GLP-1 we monitor with its current federal standing — 503A Bulks List status, PCAC review history, and any state overlay — each linked to the government document it came from and dated. Where an outcome has so far only been reported by trade press (as with the July 2026 PCAC votes), it is marked "reported" until FDA’s primary record posts, so the tracker never overstates its own sourcing. It is free to view. Monitoring, not legal advice.

The FDA drug shortage list is a primary factor in whether compounding pharmacies (503A) and outsourcing facilities (503B) may prepare copies of a drug such as semaglutide or tirzepatide. When a GLP-1 comes off the shortage list, that basis for compounding generally ends — often after a short wind-down period. We monitor the list and alert you as soon as a GLP-1’s status changes.

503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities make larger batches under tighter FDA oversight and cGMP standards. For GLP-1s, both pathways generally hinge on FDA shortage status. The distinction drives which compounded products a med spa can legally source and from whom — so a change to either pathway can affect your supply overnight.

In most states, yes. Aesthetic procedures like injectables and lasers are considered the practice of medicine, which typically requires a physician owner, a medical director, or a supervising/delegating physician relationship. The specifics — ownership rules, delegation, chart review, and how often the physician must be involved — vary by state and change through legislation, which is exactly what MedSpaRadar tracks.

A good-faith exam (GFE) is a clinical evaluation required before a patient is treated — for example before Botox or filler — to establish a valid provider-patient relationship and a treatment order. States increasingly regulate who may perform the GFE and whether it can be done over telehealth. New GFE rules are one of the most common scope-of-practice changes we surface.

It varies widely by state. Some states grant nurse practitioners broad independent authority; others require a delegating or supervising physician, an established good-faith exam, or physician availability. Because these scope-of-practice rules change through state legislation and licensing-board action, the safe answer is state-specific — and it moves. MedSpaRadar monitors all 50 states and DC for exactly these changes.

The practical challenge is awareness: rules change through hundreds of state bills plus FDA and Federal Register activity every session, and a single missed change can put a license or the business at risk. MedSpaRadar monitors all of those sources daily, scores each change for impact, and tells you in plain language what changed and what to do — so compliance starts with knowing first.

We scan all 50 state legislatures plus Washington, DC via LegiScan daily, plus federal activity from the U.S. Federal Register and the FDA — including the FDA drug-shortage database, the key signal for GLP-1 compounding legality. On top of that, a monitoring service reads 40 primary sources directly every 2 hours: 13 federal, including the Federal Register's public-inspection desk, the 21 CFR amendment log, FDA MedWatch, recalls, health-fraud alerts, criminal-enforcement announcements, federal court dockets and drug-label revisions; and 27 state — medical, osteopathic, pharmacy and nursing boards, professional-licensing offices, and attorneys general across 21 states: Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho, Massachusetts, Minnesota, Montana, New Jersey, New York, North Carolina, North Dakota, Oregon, Pennsylvania, Texas, Utah, Washington, Wisconsin. That is the monitoring scope — what we read, not what we send. Not every state has had a med-spa-relevant change yet, so you see the states that have (federal alerts apply everywhere). Every alert links directly to its primary source so you can verify it in one click.

No, and that is deliberate. Monitoring is what we read; alerts are what we send, and the second is much smaller than the first. We poll 40 primary sources every 2 hours on top of the legislative and federal sweep, and store every item with the publisher's own payload and the time we first saw it. Most of what that catches is real, sourced, and irrelevant to a practice — single-shipment border records, routine facility citations, agency notices about other industries. A human reviews what is material before anything is published, and publishing is itself a separate decision from emailing. A wider net means fewer things missed, not more things in your inbox.

We do not publish a speed figure, because we have not measured one over a long enough window to stand behind it — and an invented number is exactly the kind of claim this product exists not to make. What we can tell you is the method: sources are scanned daily, a monitoring tier polls 40 primary sources every 2 hours, and that tier includes the Federal Register's public-inspection desk, where federal documents are filed ahead of the date they publish under. Material changes are reviewed by a person and published to your feed and the weekly MedSpaRadar Brief. Every alert is human-reviewed before publishing, because a wrong compliance alert is worse than none.

Yes. There is a free, public tier that needs no subscription: peptide and GLP-1 substance standings, per-state coverage posture, and freshness metadata, documented at medsparadar.com/api. Any paid plan additionally includes API access to the cited rules corpus and the changes feed for the states that plan covers — you issue the key yourself from your dashboard, no sales call. That key is licensed for internal use: pointing your own dashboard, matter-management system, or a recurring internal check at it. Redistributing the corpus inside something you hand a third party — a client report, a portal, a product you sell — is a separate redistribution licence, scoped with us first. Every response carries its own attribution, including the LegiScan CC BY 4.0 line. Monitoring, not legal advice.

No. MedSpaRadar is regulatory monitoring, not legal, medical, or compliance advice. We surface relevant changes early and link you to the primary source so you and your counsel can act on them. Always verify against the primary source and consult qualified counsel before making compliance decisions.

Med-spa owners, injectors, nurse practitioners, medical directors, and practice managers — anyone who offers GLP-1 weight-loss programs, injectables, or other aesthetic services and cannot afford to miss a scope-of-practice or compounding change that affects their license or their business.